NCI-MATCH: T-DM1 shows promising activity in salivary gland cancer

(ECOG-ACRIN Cancer Research Group) A discovery from NCI-MATCH, the largest precision medicine cancer trial, relates to patients with salivary gland cancer treated with ado-trastuzumab emtansine (T-DM1), a drug already FDA-approved for certain types of breast cancer. Two of the three NCI-MATCH patients with this rare disease saw their tumors shrink by at least 30% with T-DM1 treatment and the benefit lasted two years for one patient and nine months for the other. Another recent trial reported similar benefits.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news